t, complement, and fibrinolytic systems, that when left unrestricted, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 4,600 people with HAE in the United States.
For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.
ViroPharma routinely posts information, including p
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE ViroPharma Incorporated|
Copyright©2009 PR Newswire.
All rights reserved
. ViroPharma to Present at Two Upcoming Healthcare Conferences2
. ViroPharma Provides 2008 Outlook3
. ViroPharma to Present at the BIO CEO & Investor Conference4
. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 20085
. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference6
. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference7
. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference8
. ViroPharma to Present at Two Upcoming Healthcare Conferences9
. Viropharma Comments On Upcoming FDA Advisory Committee Meeting10
. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs11
. ViroPharma To Acquire Lev Pharmaceuticals